Company: RCUS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001724521-25-000101
Chunk: 340

Company: Arcus Biosciences, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 2
Chunk 340
---
 Gilead Collaboration Agreement Amendment in the first quarter 2024.

See Note 5, Revenues, to our Condensed Consolidated Financial Statements in Part I, Item 1 of this report for further discussion of the amount and timing of revenues recognized from our license and collaboration agreements.

25

Research and Development Expenses

We group all of our R&D activities and the related expenditures into categories as described below:

CategoryDescriptionProgram Level ExpensesKey ClinicalTrialsLate-stage development programsR&D expenses incurred related to a Phase 3 clinical program intended to result in registration of a new product. This includes all unallocated program-level expense not directly attributable to a specific clinical trial once a molecule enters into one or more Phase 3 clinical trials.domvanalimabzimberelimabquemliclustat**ARC-10*STAR-121STAR-221PACIFIC-8PEAK-1PRISM-1Early-stage development and preclinical programsR&D expenses incurred for activities ranging from early-stage development and preclinical to Phase 2 clinical trials. This includes all unallocated program-level expense not directly attributable to a specific clinical trial unless the related program has entered into one or more Phase 3 clinical trials.quemliclustat**etrumadenantcasdatifanAB598AB801ARC-7ARC-8ARC-9ARC-20ARC-25ARC-26*ARC-27EDGE-Lung EDGE-GastriceVOLVESTELLAR-009*VELOCITY-LungVELOCITY-HNSCC***Compensation and personnel costsInternal costs, such as salaries, non-cash stock-based compensation, and other personnel expenses for our R&D employees that are not allocated to specific programs or trials.——Other costsFacilities, depreciation, and other external costs that are not recorded at the investigational product level.——Partnership reimbursementsReimbursements from our collaboration partners for shared costs incurred by us and recognized as a reduction in R&D expense.——

* Study discontinued or completed

**   Quemliclustat moved from early-stage development and preclinical program to a late-stage development program in the third quarter 2024

*** Head and Neck Squamous Cell Carcinoma ("HNSCC")

The following table summarizes our R&D expenses by category (in millions):

Three Months EndedJune 30,Six Months EndedJune 30,Category20252024Change20252024ChangeLate-stage development programs$74 $64 16 %$129 $127 2